Pacific Biosciences of California (NASDAQ:PACB – Get Rating) issued its quarterly earnings data on Wednesday. The biotechnology company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.02, Fidelity Earnings reports. Pacific Biosciences of California had a negative net margin of 130.14% and a negative return on equity of 36.11%. During the same period last year, the company posted ($0.21) EPS. Pacific Biosciences of California updated its FY 2022 guidance to EPS.
Pacific Biosciences of California Stock Up 11.5 %
Shares of NASDAQ:PACB traded up $0.60 on Thursday, hitting $5.81. 15,065,471 shares of the company's stock were exchanged, compared to its average volume of 6,306,486. The firm's 50-day moving average is $4.80 and its 200 day moving average is $7.59. The company has a market capitalization of $1.30 billion, a PE ratio of -7.20 and a beta of 1.43. Pacific Biosciences of California has a 1-year low of $3.85 and a 1-year high of $35.58. The company has a debt-to-equity ratio of 1.22, a quick ratio of 16.38 and a current ratio of 16.87.
Get
Pacific Biosciences of California alerts:
Wall Street Analysts Forecast Growth
PACB has been the topic of several recent analyst reports. Piper Sandler decreased their price objective on shares of Pacific Biosciences of California from $13.00 to $6.00 and set a "na" rating on the stock in a report on Sunday, May 15th. Cowen set a $9.00 target price on shares of Pacific Biosciences of California in a report on Tuesday, July 19th. Finally, Cantor Fitzgerald dropped their price target on shares of Pacific Biosciences of California from $23.00 to $19.00 in a research note on Thursday, May 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, Pacific Biosciences of California has an average rating of "Moderate Buy" and an average price target of $28.57.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the business. MetLife Investment Management LLC lifted its holdings in shares of Pacific Biosciences of California by 50.1% in the 1st quarter. MetLife Investment Management LLC now owns 103,966 shares of the biotechnology company's stock valued at $946,000 after purchasing an additional 34,699 shares during the last quarter. Hsbc Holdings PLC lifted its holdings in shares of Pacific Biosciences of California by 125.3% in the 1st quarter. Hsbc Holdings PLC now owns 96,953 shares of the biotechnology company's stock valued at $883,000 after purchasing an additional 53,919 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Pacific Biosciences of California in the 1st quarter valued at about $707,000. Walleye Capital LLC lifted its holdings in shares of Pacific Biosciences of California by 414.7% in the 1st quarter. Walleye Capital LLC now owns 51,225 shares of the biotechnology company's stock valued at $466,000 after purchasing an additional 41,272 shares during the last quarter. Finally, Quantbot Technologies LP lifted its holdings in shares of Pacific Biosciences of California by 1,405.2% in the 1st quarter. Quantbot Technologies LP now owns 35,793 shares of the biotechnology company's stock valued at $325,000 after purchasing an additional 33,415 shares during the last quarter. 96.72% of the stock is owned by institutional investors and hedge funds.
Pacific Biosciences of California Company Profile
(Get Rating)
Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.
Featured Articles
- Get a free copy of the StockNews.com research report on Pacific Biosciences of California (PACB)
- Chipotle Mexican Grill Or Shake Shak? Which Is The Tastier Play
- Activision Blizzard Banks On A Flurry Of New Content
- Energy Transfer Is A Value Among High-Yield Energy Infrastructure
- Warner Brothers Discovery is a Powerhouse Entertainment Play
- Devon Energy Looks Attractive if You Look Past the Headlines
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.
Pacific Biosciences of California (NASDAQ:PACB – Get Rating) issued its quarterly earnings data on Wednesday. The biotechnology company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.02, Fidelity Earnings reports. Pacific Biosciences of California had a negative net margin of 130.14% and a negative return on equity of 36.11%. During the same period last year, the company posted ($0.21) EPS. Pacific Biosciences of California updated its FY 2022 guidance to EPS.
美国加州太平洋生物科学公司(纳斯达克代码：PACB-GET Rating)周三发布了季度收益数据。这家生物技术公司公布了本季度每股收益(0.32美元)，比普遍预期的(0.34美元)高出0.02美元，富达收益报告。加州太平洋生物科学公司的净利润率为负130.14%，净资产回报率为负36.11%。去年同期，该公司公布的每股收益为0.21美元。加州太平洋生物科学公司更新了其2022财年每股收益指导。
Pacific Biosciences of California Stock Up 11.5 %
Shares of NASDAQ:PACB traded up $0.60 on Thursday, hitting $5.81. 15,065,471 shares of the company's stock were exchanged, compared to its average volume of 6,306,486. The firm's 50-day moving average is $4.80 and its 200 day moving average is $7.59. The company has a market capitalization of $1.30 billion, a PE ratio of -7.20 and a beta of 1.43. Pacific Biosciences of California has a 1-year low of $3.85 and a 1-year high of $35.58. The company has a debt-to-equity ratio of 1.22, a quick ratio of 16.38 and a current ratio of 16.87.
纳斯达克：太平洋投资银行股价周四上涨0.6美元，至5.81美元。该公司股票成交量为15,065,471股，而其平均成交量为6,306,486股。该公司的50日移动均线切入位在4.80美元，200日移动均线切入位在7.59美元。该公司市值为13亿美元，市盈率为-7.20，贝塔系数为1.43。加州太平洋生物科学公司的一年低点为3.85美元，一年高位为35.58美元。该公司的负债权益比率为1.22，速动比率为16.38，流动比率为16.87。
Get
Pacific Biosciences of California
alerts:
Wall Street Analysts Forecast Growth
PACB has been the topic of several recent analyst reports. Piper Sandler decreased their price objective on shares of Pacific Biosciences of California from $13.00 to $6.00 and set a "na" rating on the stock in a report on Sunday, May 15th. Cowen set a $9.00 target price on shares of Pacific Biosciences of California in a report on Tuesday, July 19th. Finally, Cantor Fitzgerald dropped their price target on shares of Pacific Biosciences of California from $23.00 to $19.00 in a research note on Thursday, May 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, Pacific Biosciences of California has an average rating of "Moderate Buy" and an average price target of $28.57.
PACB一直是最近几份分析师报告的主题。派珀·桑德勒在5月15日周日的一份报告中将其对加州太平洋生物科学公司股票的目标价从13.00美元下调至6.00美元，并对该股设定了“NA”评级。考恩在7月19日星期二的一份报告中为加州太平洋生物科学公司的股票设定了9.00美元的目标价。最后，坎托·菲茨杰拉德在5月5日星期四的一份研究报告中将加州太平洋生物科学公司的股票目标价从23.00美元下调至19.00美元。一名投资分析师对该股的评级为卖出，一名分析师对该公司股票的评级为持有，四名分析师对该公司股票的评级为买入。根据MarketBeat的数据，加州太平洋生物科学公司的平均评级为“中等买入”，平均目标价为28.57美元。
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the business. MetLife Investment Management LLC lifted its holdings in shares of Pacific Biosciences of California by 50.1% in the 1st quarter. MetLife Investment Management LLC now owns 103,966 shares of the biotechnology company's stock valued at $946,000 after purchasing an additional 34,699 shares during the last quarter. Hsbc Holdings PLC lifted its holdings in shares of Pacific Biosciences of California by 125.3% in the 1st quarter. Hsbc Holdings PLC now owns 96,953 shares of the biotechnology company's stock valued at $883,000 after purchasing an additional 53,919 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Pacific Biosciences of California in the 1st quarter valued at about $707,000. Walleye Capital LLC lifted its holdings in shares of Pacific Biosciences of California by 414.7% in the 1st quarter. Walleye Capital LLC now owns 51,225 shares of the biotechnology company's stock valued at $466,000 after purchasing an additional 41,272 shares during the last quarter. Finally, Quantbot Technologies LP lifted its holdings in shares of Pacific Biosciences of California by 1,405.2% in the 1st quarter. Quantbot Technologies LP now owns 35,793 shares of the biotechnology company's stock valued at $325,000 after purchasing an additional 33,415 shares during the last quarter. 96.72% of the stock is owned by institutional investors and hedge funds.
几家机构投资者和对冲基金最近改变了他们在该业务中的头寸。大都会人寿投资管理有限责任公司在第一季度增持了加州太平洋生物科学公司的股票50.1%。大都会人寿投资管理有限责任公司现在拥有103,966股生物技术公司的股票，价值946,000美元，在上个季度又购买了34,699股。汇丰控股在第一季度增持了加州太平洋生物科学公司的股票125.3%。汇丰控股在上个季度购买了53,919股后，现在持有这家生物技术公司96,953股股票，价值883,000美元。Dynamic Technology Lab Private Ltd在第一季度购买了加州太平洋生物科学公司的新股份，价值约70.7万美元。Walleye Capital LLC在第一季度增持了加州太平洋生物科学公司的股票414.7%。Walleye Capital LLC现在拥有51,225股这家生物技术公司的股票，价值46.6万美元，在上个季度又购买了41,272股。最后，Quantbot Technologies LP在第一季度增持了加州太平洋生物科学公司的股份1,405.2%。Quantbot Technologies LP现在拥有这家生物技术公司35,793股股票，价值325,000美元，在上个季度又购买了33,415股。96.72%的股票由机构投资者和对冲基金持有。
Pacific Biosciences of California Company Profile
Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.
加州太平洋生物科学公司设计、开发和制造测序系统，以解决基因复杂的问题。该公司提供进行、监测和分析生化测序反应的PacBio系统；消耗品，包括单分子实时(SMRT)细胞；以及为特定工作流程设计的各种试剂盒，如将DNA转化为SMRTbell双链DNA文库格式的模板制备试剂盒，包括连接酶、缓冲液和核酸外切酶等分子生物学试剂。
Featured Articles
- Get a free copy of the StockNews.com research report on Pacific Biosciences of California (PACB)
- Chipotle Mexican Grill Or Shake Shak? Which Is The Tastier Play
- Activision Blizzard Banks On A Flurry Of New Content
- Energy Transfer Is A Value Among High-Yield Energy Infrastructure
- Warner Brothers Discovery is a Powerhouse Entertainment Play
- Devon Energy Looks Attractive if You Look Past the Headlines
- 免费获取StockNews.com关于加州太平洋生物科学的研究报告(PACB)
- 墨西哥烧烤鸡尾酒还是奶昔？哪一出戏更有味道
- Activision Blizzard推出一系列新内容
- 能源转移是高产出能源基础设施的价值所在
- 华纳兄弟探索是Powerhouse娱乐公司的一部戏剧
- 如果你不去看头条新闻，德文能源看起来很有吸引力
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.
获得《加州日报》太平洋生物科学的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对加利福尼亚州太平洋生物科学公司和相关公司的最新新闻和分析师评级的每日简要摘要。
